<DOC>
	<DOCNO>NCT01929603</DOCNO>
	<brief_summary>This 2-part study patient advance solid tumour . Part A investigate effect rifampicin PK parameter olaparib patient ; Part B allow patient continue access olaparib PK phase provide additional safety data .</brief_summary>
	<brief_title>Study Assess Effect Rifampicin ( CYP Inducer ) Blood Levels Safety Olaparib Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>For inclusion study , patient fulfil follow criterion : 1 . Provision write informed consent prior studyspecific procedure . 2 . Patients age great equal 18 year . 3 . Histologically , appropriate , cytologically confirm malignant solid tumour refractory resistant standard therapy suitable effective standard therapy exist . 4 Patients must normal organ bone marrow function measure within 28 day prior administration investigational product ( IP ) define : Haemoglobin ( Hb ) great equal 10.0 g/dL , blood transfusion previous 28 day . Absolute neutrophil count ( ANC ) great equal 1.5 x 109/L . White blood cell ( WBC ) great 3 x 109/L . Platelet count great equal 100 x 109/L . Total bilirubin less equal 1.5 x institutional upper limit normal ( ULN ) ( except case Gilbert 's disease ) . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) less equal 2.5 x institutional ULN unless liver metastasis present , case must less equal 5x ULN , Serum creatinine less equal 1.5 x institutional ULN . 5 . Calculated serum creatinine clearance great 50 mL/min ( use CockroftGault formula 24 hour urine collection ) . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 . 7 . Patients must life expectancy great equal 16 week . 8 . Evidence nonchildbearing status woman childbearing potential , post menopausal status : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment Day 1 Part A. Postmenopausal define : Amenorrheic 1 year follow cessation exogenous hormonal treatment . Luteinising hormone follicle stimulate hormone level post menopausal range woman 50 year age . Radiationinduced oophorectomy last menses great 1 year ago . Chemotherapyinduced menopause great 1 year interval since last menses . Surgical sterilisation ( bilateral oophorectomy hysterectomy ) . 9 . Patients willing able comply protocol duration study include undergoing treatment schedule visit examination . 10 . Patients must stable concomitant medication regimen ( exception electrolyte supplement ) , define change medication dose within 2 week prior start olaparib dose , except bisphosphonates , denosumab , corticosteroid , stable dose least 4 week prior start olaparib dosing . Patients enter study follow exclusion criterion fulfil . 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff , agent , and/or staff study site ) . 2 . Previous enrolment present study . 3 . Participation another clinical study IP last 14 day ( long period depend defined characteristic agent use ) . 4 . Patients receive systemic chemotherapy radiotherapy ( except palliative reason ) within 2 week prior study treatment ( long period depend defined characteristic agent use ) . The patient receive stable dose bisphosphonates denosumab bone metastasis , study , long start least 4 week prior treatment . 5 . Patients receive receive inhibitor inducer CYP3A4 . 6 . Toxicities ( great equal Common Toxicity Criteria Adverse Events [ CTCAE ] Grade 2 ) cause previous cancer therapy , exclude alopecia . 7 . Any intake grapefruit , grapefruit juice , Seville oranges , Seville orange marmalade , product contain grapefruit Seville oranges within 7 day first administration IP end Part A . 8 . Patients brain metastasis . A scan confirm absence brain metastasis require . 9 . Major surgery within 2 week start study treatment patient must recover effect major surgery . 10 . Patients consider poor medical risk due serious uncontrolled medical disorder , non malignant systemic disease , uncontrolled seizure , active uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 3 month ) myocardial infarction , uncontrolled major seizure disorder , unstable spinal cord compression , superior vena cava syndrome , extensive bilateral interstitial lung disease high resolution computer tomography ( HRCT ) scan , psychiatric disorder prohibits obtain informed consent . 11 . Patients diabetes mellitus . 12 . Patients gastric , gastrooesophageal , oesophageal cancer . 13 . Patients unable swallow orally administer medication patient gastrointestinal disorder significant gastrointestinal resection likely interfere absorption olaparib . 14 . Breastfeeding woman . 15 . Immunocompromised patient , eg , patient know serologically positive human immunodeficiency virus ( HIV ) . 16 . Patients know active hepatic disease ( eg , hepatitis B C ) . 17 . Patients know hypersensitivity rifampicin excipients product . 18 . Patients know hypersensitivity olaparib excipients product . 19 . Resting electrocardiogram ( ECG ) screen measurable QT interval ( QT ) correct heart rate ( QTc ) great 470 msec 2 time point within 24 hour period family history long QT syndrome . 20 . Concomitant medication contraindicate use rifampicin ( include , limited ) : atazanavir , darunavir , fosamprenavir , ritonavirboosted saquinavir , saquinavir , tipranavir . 21 . Patients jaundice . 22 . Patients weigh less 50 kg . 23 . Clinical judgment investigator patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>oncology , cancer , tumour , anticancer drug , pharmacokinetics , olaparib , rifampicin , neoplasm , CYP P450 inducer</keyword>
</DOC>